National Health Research Institutes

Chung Yuan Christian University

Anbogen Therapeutics, Inc

Other

International Chlorella Co., Ltd.

Tsu-An Hsu

Yu-Sheng Chao

Hsing-Pang Hsieh

Jyh-Haur Chern

Shin-Ru Shih

Yen-Chun Lee

Chung-Chi Lee

Li-Wen Wang

Iou-Jiun Kang

Chuan Shih

Tzong-Yuan Wu

Ying-Ju Chen

Suey-Sheng Kao

Tzyy-Rong Jinn

Selvaraj Mohane Coumar

Shin-Jhan Zeng

Wen-Hsing Lin

Sue-Ming Chang

Chia-Liang Tai

Kak-Shan Shia

Weir-Torn Jiaang

Chien-Fu Huang

Jia-Tsrong Jan

Chi-Min Chen

Xin Chen

Feng-Shiun Shie

Hwan-Wun Liu

Su-Ying Wu

Neeraj Mahindroo

Hui-Chen Hung

Teng-Yuan Chang

Shun Te Wang

Yueh Andrew Yueh

Sheng-Ju Hsu

Yen-Shian Wu

Yu-Cheng Chou

Yi-Rong Chen

Jiann-Yih Yeh

Santai Shen

Mohane Selvaraj Coumar

Disclosed herein is a specific crystalline forms of (E)-N-hydroxy-3-(1-(phenylsulfonyl) indolin-5-yl) acrylamide (ABT-301), the pharmaceutical composition and capsule comprising the same, the intermediate and the medical application thereof. Said crystalline forms of ABT-301 can exhibit unexpected stability and improved pharmacokinetic properties compared to other forms or salt thereof, thereby allowing said compound more suitable for drug development and satisfying the requirements for bioavailability and drug efficacy.

Crystalline forms of (E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide

Disclosed herein is a specific crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide (ABT-101) free base, the pharmaceutical composition and capsule comprising the same, and the medical application thereof. Said crystalline forms of ABT-101 free base can exhibit unexpected stability and improved pharmacokinetic properties compared to other forms or salt thereof, thereby allowing said compound more suitable for drug development and satisfying the requirements for bioavailability and drug efficacy.

Crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2- enamide free base

Isolated antibodies that bind specifically to R-spondin 3 (RSPO3) are described. Also described herein are compositions containing the antibodies and methods of using the antibodies to treat cancer and detect RSPO3.

Antibodies to R-spondin 3

An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14; a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15; a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24; a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25; a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26; and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to A&#x3b2;or an N-terminal modified form thereof.

Anti-Abeta antibodies and uses thereof

A compound of formula (I): wherein A, B, D, X, Y, R, R, R, m, p, and q are defined herein. Also disclosed is a method for inhibiting FMS-like tyrosine kinase 3, aurora kinase, or vascular endothelial growth factor receptor.

Pyrazole compounds and thiazole compounds as protein kinases inhibitors

Quinoline compounds of formula (I): in which A, B, D, E, F, G, R, R, R, X, Y, n, p, and q are defined herein. Also disclosed is a method for treating a viral infection with a compound of formula (I).

Quinoline compounds and their use for treating viral infection

Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.

Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors

Fused bicyclic pyrimidine compounds of formula (I): wherein R, R, R, X, X, Y, Z, A, B, C, D, n, and the twobonds are defined herein. Also disclosed are a method for inhibiting Aurora kinase activity and a method for treating cancer with these compounds.

Fused bicyclic pyrimidine compounds as aurora kinase inhibitors

An invention relates to an extract of, which contains myristic acid, palmitic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, and stearic acid. Also related is use of this extract to treat diabetes, obesity, and dyslipidaemia.

[object Object]

A compound of the following formula: in which R, R, R, U, V, T, W, X, Y, Z, m, n, p, x, y, and z are as defined herein. Also disclosed are (1) a pharmaceutical composition containing such a compound, and (2) a method for treating Hepatitis C virus infection using such a compound.

Hepatitis C virus inhibitors

Imidazolidinone and imidazolinethione compounds of formula (I): wherein R, R, R, A, A, X, Y, Z, m, n, p, x, and y are defined herein. Also disclosed is a method of treating hepatitis C virus infection with these compounds.

Imidazolidinone and imidazolidinethione derivatives

Thiourea compounds of the following formula: wherein n, R, R, R, A, A, X, Y, and Z are defined herein. Also disclosed is a method of treating hepatitis C virus infection with these compounds.

Thiourea derivatives

The present invention relates to use of bicistronic DNA constructs for identifying compounds that inhibits IRES-dependent translation activity of an infectious enterovirus (EV) or encephalomyocarditis virus (EMCV) without affecting CAP-dependent translation activity of a host subject. The compounds thus identified are useful in preparation of a medicament for treating EV or EMCV infection.

Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation

A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine, thioridazine, chlorprothixene, thiothixene, clozapine, haloperidol, haloperidol decanoate, loxapine, molindone, olanzapine, pimozide, quetiapine, risperidone, and amitriptyline.

Treatment of coronavirus infection

This invention relates to treating peroxisome proliferator-activated receptors related diseases with certain indole compounds. The indole compounds are of formula (I) below. Each variable is defined in the specification. 

Indole compounds

Growing community of inventors

Taipei, Taiwan

Tsu-An Hsu